Table 1.
Study Participant Baseline Characteristics
| Age Group |
|||
|---|---|---|---|
| 4–8 y, n = 54 (35%) | 9–17 y, n = 51 (33%) | 18–24 y, n = 50 (32%) | |
| Sex, male | 54% | 57% | 42% |
| Race | |||
| Black | 65% | 55% | 64% |
| White | 26% | 39% | 30% |
| Ethnicity | |||
| Hispanic | 33% | 39% | 24% |
| Age, y (median) | 6 | 14 | 19 |
| CD4 count, cells/μL, median (range) | 1161 (308–1921) | 642 (113–1488) | 589 (57–1031) |
| CD4%, median (range) | 37% (24–50) | 33% (11–47) | 30% (5–48) |
| Viral load, copies/mL, median (range) | 48 (40–19K) | 48 (40–80K) | 75 (40–81K) |
| Baseline ART | |||
| Combination ARTa | 50 | 45 | 42 |
| Otherb | 1 | 3 | 4 |
| None | 3 | 3 | 4 |
Abbreviation: ART, antiretroviral therapy.
a Combination ART is defined as a regimen containing at least 3 antiretroviral drugs from at least 2 drug classes.
b Includes regimens with nucleoside reverse transcriptase inhibitor only, combination protease inhibitor and nonnucleoside reverse transcriptase inhibitor, and other combinations of antiretroviral agents.